Now live: Pro — the full 13F research suite for serious investorsSee pricing →
GREAT POINT PARTNERS LLC

Q2 2024 · 13F-HR

GREAT POINT PARTNERS LLCholdings as filed

Filed 2024-08-14 · accession 0001172661-24-003577

$522.0M
Reported value
33
Positions
2024-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
M96088105URGNUROGEN PHARMA LTD$48.8M9.34%2,906,259CommonSHARED
64135M105NGNENEUROGENE INC$36.5M7.00%1,004,291CommonSHARED
00370M103ABVXABIVAX SA$32.7M6.26%2,472,188CommonSHARED
N5749R1002GHMERUS N V$31.0M5.93%523,288CommonSHARED
729139105PLRXPLIANT THERAPEUTICS INC$28.3M5.43%2,636,864CommonSHARED
03940C100ACLXGBXARCELLX INC$27.2M5.20%492,000CommonSHARED
268158201DVAXDYNAVAX TECHNOLOGIES CORP$26.7M5.11%2,374,000CommonSHARED
30052C107EOLSEVOLUS INC$26.6M5.10%2,451,772CommonSHARED
23282W605CYTKCYTOKINETICS INC$25.7M4.92%474,202CommonSHARED
252828108DNTHDIANTHUS THERAPEUTICS INC$19.6M3.76%757,929CommonSHARED
457669307INSMINSMED INC$16.8M3.21%250,000CommonSHARED
G9TY5A101ZURAZURA BIO LTD$16.2M3.11%4,642,241CommonSHARED
483497103KALVKALVISTA PHARMACEUTICALS INC$15.8M3.02%1,338,568CommonSHARED
462222100IONSIONIS PHARMACEUTICALS INC$15.7M3.01%330,000CommonSHARED
21077P108CNTXCONTEXT THERAPEUTICS INC$14.9M2.85%7,419,355CommonSHARED
03152W109AM6AMICUS THERAPEUTICS INC$14.8M2.84%1,495,500CommonSHARED
68404V100OPTINOSE INC$14.3M2.73%13,727,097CommonSHARED
29664W105ESPRESPERION THERAPEUTICS INC NE$12.9M2.46%5,791,594CommonSHARED
92915B106VYGRVOYAGER THERAPEUTICS INC$12.7M2.43%1,601,527CommonSHARED
69012T305OTLKOUTLOOK THERAPEUTICS INC$12.6M2.41%1,701,510CommonSHARED
05280R100AUTLAUTOLUS THERAPEUTICS PLC$12.0M2.29%3,441,667CommonSHARED
471871202JSPRJASPER THERAPEUTICS INC$9.1M1.75%402,015CommonSHARED
68062P106OLMAOLEMA PHARMACEUTICALS INC$8.6M1.65%796,880CommonSHARED
880881107430TERNS PHARMACEUTICALS INC$7.8M1.50%1,149,406CommonSHARED
92790C104VRDNVIRIDIAN THERAPEUTICS INC$6.5M1.25%500,000CommonSHARED
89854M101TCRXTSCAN THERAPEUTICS INC$5.5M1.05%940,831CommonSHARED
92840H400VTGNVISTAGEN THERAPEUTICS INC$5.3M1.02%1,529,338CommonSHARED
G4444H101BBOTHELIX ACQUISITION CORP II$5.1M0.98%500,000CommonSHARED
74587V107PBYIPUMA BIOTECHNOLOGY INC$4.8M0.93%1,486,544CommonSHARED
501976104KYTXKYVERNA THERAPEUTICS INC$3.7M0.72%499,152CommonSHARED
00773J202SYRESPYRE THERAPEUTICS INC$3.2M0.61%134,612CommonSHARED
032724106ANABANAPTYSBIO INC$626,5000.12%25,000CommonSHARED
528872302LXRXLEXICON PHARMACEUTICALS INC$50,4000.01%30,000CommonSHARED

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.